{
    "doi": "https://doi.org/10.1182/blood.V118.21.3591.3591",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1933",
    "start_url_page_num": 1933,
    "is_scraped": "1",
    "article_title": "Improved Survival Rates Among Acute Myeloid Leukemia (AML) Patients 65 to 74 Years: Population-Based Estimates Over Three Decades, ",
    "article_date": "November 18, 2011",
    "session_type": "613. Acute Myeloid Leukemia - Biology and Pathophysiology: Poster III",
    "abstract_text": "Abstract 3591 Background: AML is the common acute leukemia in adults, accounting for approximately 90% of all acute leukemias in those over the age of 18 years. Overall survival remains poor, with <50% 5-year survival in patients under 45 years and <5% in those over 65 years. We examined whether there has been improvement in survival over three successive decades for subsets of geriatric AML patients. Methods: Examining data from the Surveillance, Epidemiology and End Results (SEER) database, we determined relative overall survival (+/\u2212 standard error) of patients with AML 65\u201374, 75\u201384 and 85+ years of age between 1977\u201386, 1987\u201396 and 1997\u20132006. Results: Survival for both males and females at 12, 24 and 36 months post-diagnosis is shown below. Between 1977\u20131986 and 1987\u20131996, 12-month, 24-month and 36-month survival rates increased from 20% to 25%, 10% to 13.1%, and 5.5 to 8.4%, respectively, in the 65\u201374 year age group. Between 1987\u20131996 and 1997\u20132006, 12-month, 24-month and 36-month survival rates increased from 25% to 30%, 13% to 17% and 8.4% to 11.7%, respectively, in the same age group. Survival rates increased over each decade in patients younger than 75 years of age, but did not improve significantly in patients 75 years and older. Female patients exhibited better survival up to 24 months than males in all age categories. The oldest-old (85+ years) had the lowest survival rates, with no apparent improvement over the past 3 decades for either gender. Conclusions: Analysis of a large data-set demonstrated that overall survival remains unsatisfactory over a 3-decade period among older patients, but has in fact improved in the young-old (65\u201374 year age group). Neither standard nor newly developed chemotherapy regimens have favorably impacted survival for the oldest-old AML patients, and intervention in this age group is best undertaken on a clinical trial. Table: Relative Survival Rates for Acute Myeloid Leukemia  . Survival \u00b1 Standard Error % (Male) . Survival \u00b1 Standard Error % (Female) . Age (yrs) . 12 months . 24 months . 36 months . 12 months . 24 months . 36 months .  Year (1977 to 1986)  Year (1977 to 1986)  All  29.1\u00b10.90 (n=2973) 16.1\u00b10.7 11.4\u00b10.6 31.3\u00b11.0 (n=2420) 18.7\u00b10.8 14.3\u00b10.8 65 to 74  20.1\u00b11.5 (n=727) 10.0\u00b11.2 5.5\u00b10.9 16.3\u00b11.7 (n=490) 9.6\u00b11.4 5.5\u00b11.1 75 to 84  10.3\u00b11.3 (n=584) 3.3\u00b10.8 2.3\u00b10.7 14.9\u00b11.6 (n=531) 7.8\u00b11.2 5.0\u00b11 \u226585  10.6\u00b12.7 (n=160) 7.0\u00b12.4 4.4\u00b12.2 9.3\u00b12.1 (n=224) 5.3\u00b11.7 3.4\u00b11.5  Year (1987 to 1996)  Year (1987 to 1996)  All  34.8\u00b10.8 (n=3360) 20.7\u00b10.7 16.5\u00b10.7 36.0\u00b10.9 (n=2861) 24.1\u00b10.8 19.9\u00b10.8 65 to 74  25.1\u00b11.5 (n=913) 12.3\u00b11.1 7.5\u00b10.9 26.1\u00b11.8 (n=607) 14.0\u00b11.4 9.4\u00b11.2 75 to 84  11\u00b10\u00b11.3 (n=660) 4.1\u00b10.8 2.7\u00b10.7 11.6\u00b11.3 (n=608) 6.2\u00b11.0 3.9\u00b10.9 \u226585  6.8\u00b12.2 (n=159) 1.7\u00b11.2 0.0\u00b10 4.8\u00b11.4 (n=264) 1.9\u00b10.9 1.1\u00b10.8  Year (1997 to 2006)  Year (1997 to 2006)  All  39.1\u00b10.8 (n=4078) 27.4\u00b10.8 23.7\u00b10.8 40.9\u00b10.9 (n=3480) 30.5\u00b10.9 26.9\u00b10.9 65 to 74  30.3\u00b11.6 (n=943) 15.8\u00b11.3 9.8\u00b11.1 30.7\u00b11.9(n=662) 18.4\u00b11.6 13.7\u00b11.5 75 to 84  14.8\u00b11.3 (n=896) 5.0\u00b10.8 3.5\u00b10.8 14.9\u00b11.3(n=831) 6.4\u00b10.9 3.3\u00b10.70 \u226585  7.8\u00b11.8 (n=268) 1.7\u00b11 1.2\u00b10.8 7.3\u00b11.5(n=364) 1.0\u00b10.7 0.6\u00b10.6 . Survival \u00b1 Standard Error % (Male) . Survival \u00b1 Standard Error % (Female) . Age (yrs) . 12 months . 24 months . 36 months . 12 months . 24 months . 36 months .  Year (1977 to 1986)  Year (1977 to 1986)  All  29.1\u00b10.90 (n=2973) 16.1\u00b10.7 11.4\u00b10.6 31.3\u00b11.0 (n=2420) 18.7\u00b10.8 14.3\u00b10.8 65 to 74  20.1\u00b11.5 (n=727) 10.0\u00b11.2 5.5\u00b10.9 16.3\u00b11.7 (n=490) 9.6\u00b11.4 5.5\u00b11.1 75 to 84  10.3\u00b11.3 (n=584) 3.3\u00b10.8 2.3\u00b10.7 14.9\u00b11.6 (n=531) 7.8\u00b11.2 5.0\u00b11 \u226585  10.6\u00b12.7 (n=160) 7.0\u00b12.4 4.4\u00b12.2 9.3\u00b12.1 (n=224) 5.3\u00b11.7 3.4\u00b11.5  Year (1987 to 1996)  Year (1987 to 1996)  All  34.8\u00b10.8 (n=3360) 20.7\u00b10.7 16.5\u00b10.7 36.0\u00b10.9 (n=2861) 24.1\u00b10.8 19.9\u00b10.8 65 to 74  25.1\u00b11.5 (n=913) 12.3\u00b11.1 7.5\u00b10.9 26.1\u00b11.8 (n=607) 14.0\u00b11.4 9.4\u00b11.2 75 to 84  11\u00b10\u00b11.3 (n=660) 4.1\u00b10.8 2.7\u00b10.7 11.6\u00b11.3 (n=608) 6.2\u00b11.0 3.9\u00b10.9 \u226585  6.8\u00b12.2 (n=159) 1.7\u00b11.2 0.0\u00b10 4.8\u00b11.4 (n=264) 1.9\u00b10.9 1.1\u00b10.8  Year (1997 to 2006)  Year (1997 to 2006)  All  39.1\u00b10.8 (n=4078) 27.4\u00b10.8 23.7\u00b10.8 40.9\u00b10.9 (n=3480) 30.5\u00b10.9 26.9\u00b10.9 65 to 74  30.3\u00b11.6 (n=943) 15.8\u00b11.3 9.8\u00b11.1 30.7\u00b11.9(n=662) 18.4\u00b11.6 13.7\u00b11.5 75 to 84  14.8\u00b11.3 (n=896) 5.0\u00b10.8 3.5\u00b10.8 14.9\u00b11.3(n=831) 6.4\u00b10.9 3.3\u00b10.70 \u226585  7.8\u00b11.8 (n=268) 1.7\u00b11 1.2\u00b10.8 7.3\u00b11.5(n=364) 1.0\u00b10.7 0.6\u00b10.6 View Large Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "leukemia, myelocytic, acute",
        "survival rate",
        "leukemia, acute",
        "chemotherapy regimen",
        "standard error",
        "aged adult, 80 and over",
        "older adult"
    ],
    "author_names": [
        "Mya S Thein, MD",
        "Ahmedin Jemal",
        "Maria R. Baer, MD",
        "William B Ershler, MD",
        "Jerome W Yates, MD, MPH"
    ],
    "author_affiliations": [
        [
            "Hematology and Oncology, University of MD/National Institute on Aging, Baltimore, MD, USA, "
        ],
        [
            "Surveillance Research, American Cancer Society, Atlanta, GA, USA, "
        ],
        [
            "Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA, "
        ],
        [
            "National Institute on Aging, Baltimore, MD, USA"
        ],
        [
            "National Institute on Aging, Baltimore, MD, USA"
        ]
    ],
    "first_author_latitude": "39.29263470000001",
    "first_author_longitude": "-76.5490058"
}